EE05429B1 - Karbokslhappe amiidi derivaadid, nende saamise meetod ning kasutamine - Google Patents

Karbokslhappe amiidi derivaadid, nende saamise meetod ning kasutamine

Info

Publication number
EE05429B1
EE05429B1 EEP200400058A EEP200400058A EE05429B1 EE 05429 B1 EE05429 B1 EE 05429B1 EE P200400058 A EEP200400058 A EE P200400058A EE P200400058 A EEP200400058 A EE P200400058A EE 05429 B1 EE05429 B1 EE 05429B1
Authority
EE
Estonia
Prior art keywords
sub
alkyl
sup
hydrogen
groups
Prior art date
Application number
EEP200400058A
Other languages
English (en)
Estonian (et)
Inventor
Dom βny Gy�rgy
Horv βth Csilla
βndor Farkas S
Bart βn� Szalai Gisella
Nagy J�zsef
βndor Kolok S
Kov βcsn� Boz� �va
βn Borza Istv
βn V βg� Istv
Bielik Attila
Ign βczn� Szendrei Gy�rgyi
Keseru Gy�rgy
Original Assignee
Richter Gedeon Vegy�szeti Gy βr Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0103055A external-priority patent/HU226978B1/hu
Priority claimed from HU0202213A external-priority patent/HU225905B1/hu
Application filed by Richter Gedeon Vegy�szeti Gy βr Rt. filed Critical Richter Gedeon Vegy�szeti Gy βr Rt.
Publication of EE200400058A publication Critical patent/EE200400058A/xx
Publication of EE05429B1 publication Critical patent/EE05429B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
EEP200400058A 2001-07-24 2002-07-23 Karbokslhappe amiidi derivaadid, nende saamise meetod ning kasutamine EE05429B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0103055A HU226978B1 (en) 2001-07-24 2001-07-24 New carboxylic acid amide compounds, process for their preparation and pharmaceutical compositions containing them and their use
HU0202213A HU225905B1 (en) 2002-07-10 2002-07-10 Solid-supported parallel synthesis of new carboxylic acid amide derivatives
PCT/HU2002/000071 WO2003010159A1 (en) 2001-07-24 2002-07-23 Piperidine derivatives as nmda receptor antagonists

Publications (2)

Publication Number Publication Date
EE200400058A EE200400058A (et) 2004-04-15
EE05429B1 true EE05429B1 (et) 2011-06-15

Family

ID=90001553

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200400058A EE05429B1 (et) 2001-07-24 2002-07-23 Karbokslhappe amiidi derivaadid, nende saamise meetod ning kasutamine

Country Status (32)

Country Link
US (1) US7435744B2 (enExample)
EP (1) EP1409477B1 (enExample)
JP (1) JP4322113B2 (enExample)
KR (1) KR100890676B1 (enExample)
CN (1) CN100413860C (enExample)
AT (1) ATE408611T1 (enExample)
AU (1) AU2002313566B2 (enExample)
BG (1) BG66441B1 (enExample)
BR (1) BR0211393A (enExample)
CA (1) CA2453383C (enExample)
CO (1) CO5560570A2 (enExample)
CY (1) CY1109401T1 (enExample)
CZ (1) CZ2004233A3 (enExample)
DE (1) DE60228969D1 (enExample)
DK (1) DK1409477T3 (enExample)
EA (1) EA010162B1 (enExample)
EE (1) EE05429B1 (enExample)
ES (1) ES2312603T3 (enExample)
HR (1) HRP20040178B1 (enExample)
IL (1) IL159393A (enExample)
IS (1) IS7066A (enExample)
MX (1) MXPA04000737A (enExample)
NO (1) NO327099B1 (enExample)
NZ (1) NZ530055A (enExample)
PL (1) PL216636B1 (enExample)
PT (1) PT1409477E (enExample)
RS (1) RS50767B (enExample)
SI (1) SI1409477T1 (enExample)
SK (1) SK287726B6 (enExample)
UA (1) UA77684C2 (enExample)
WO (1) WO2003010159A1 (enExample)
ZA (1) ZA200400417B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10210779A1 (de) * 2002-03-12 2003-10-09 Merck Patent Gmbh Cyclische Amide
PA8575901A1 (es) * 2002-07-18 2004-07-20 Pfizer Prod Inc Derivados de piperidina novedosos
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
EP1670787B1 (en) 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
JP4737418B2 (ja) * 2003-09-25 2011-08-03 塩野義製薬株式会社 Ｎｍｄａ受容体拮抗作用を有するピペリジン誘導体
WO2005039564A1 (en) * 2003-10-02 2005-05-06 Vertex Pharmaceuticals Incorporated Phthalimide compounds useful as protein kinase inhibitors
HUP0401522A2 (en) * 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HU227000B1 (en) * 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
HUP0600810A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
EP1918281A1 (en) * 2006-11-02 2008-05-07 Laboratorios del Dr. Esteve S.A. Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2009025265A1 (ja) * 2007-08-21 2009-02-26 Shionogi & Co., Ltd. ピペラジン誘導体
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
MY161831A (en) * 2007-10-27 2017-05-15 Richter Gedeon Nyrt New non-peptide derivatives as bradykinin b1 antagonists
CA2730253A1 (en) * 2008-07-08 2010-01-14 Alphonso Higuera Novel crystalline form of 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-n-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-acetamide
US20110190347A1 (en) * 2008-08-21 2011-08-04 Richter Gedeon Nyrt. Methods for treating neuropathic pain
CA2734859A1 (en) * 2008-08-21 2010-02-25 Richter Gedeon Nyrt. Methods for treating cns disorders
WO2010068794A2 (en) 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
HUP0900130A3 (en) 2009-03-03 2012-02-28 Richter Gedeon Nyrt Novel crystalline hydrate, amorphous and polymorphic forms of dihydro-benzoxazole-6-yl-acetamide derivative and processes for their preparation
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
CN102753019A (zh) 2009-12-15 2012-10-24 纽罗普公司 用于治疗神经系统病症的化合物
JP2013519722A (ja) 2010-02-16 2013-05-30 ファイザー・インク （ｒ）−４−（（４−（（４−（テトラヒドロフラン−３−イルオキシ）ベンゾ［ｄ］イソオキサゾール−３−イルオキシ）メチル）ピペリジン−１−イル）メチル）テトラヒドロ−２ｈ−ピラン−４−オール、５−ｈｔ４受容体の部分アゴニスト
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
HUP1000424A2 (en) 2010-08-11 2012-05-02 Richter Gedeon Nyrt Use of radiprodil in attention deficit hyperactivity disorder
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
ES2647442T3 (es) * 2011-12-27 2017-12-21 Bayer Intellectual Property Gmbh Compuestos intermedios para la preparación de derivados de heteroarilpiperidina y de heteroarilpiperazina como fungicidas
AU2013251079B2 (en) 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
US9868730B2 (en) 2013-02-18 2018-01-16 The Trustees Of Columbia University In The City Of New York Kappa opioid receptor selective compounds, compositions, and uses thereof
JP2017538678A (ja) * 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
WO2017053769A1 (en) * 2015-09-25 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Triazole derivatives as p2y14 receptor antagonists
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
ES2897050T3 (es) 2017-12-08 2022-02-28 Boehringer Ingelheim Int Derivados de imidazopiridina y el uso de los mismos como medicamento
EP3724177A1 (en) * 2017-12-12 2020-10-21 Phenex Discovery Verwaltungs-GmbH Oxalamides as modulators of indoleamine 2,3-dioxygenase
TW202035395A (zh) * 2018-10-17 2020-10-01 德商百靈佳殷格翰國際股份有限公司 4-嘧啶-5-基甲基-嗎啉衍生物及其作為藥物之用途
JP7093469B2 (ja) 2018-10-17 2022-06-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４－ピリジニルメチル－モルホリン誘導体および医薬としてのその使用
PE20211278A1 (es) * 2018-10-17 2021-07-19 Boehringer Ingelheim Int Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
WO2020245136A1 (en) 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
CN113234036B (zh) * 2021-05-12 2023-07-14 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途
MX2024001744A (es) 2021-08-06 2024-04-23 Grin Therapeutics Inc Formulaciones de radiprodil.
CN114163388A (zh) * 2021-12-15 2022-03-11 陕西汉江药业集团股份有限公司 芬苯达唑中的杂质i、杂质ⅱ和杂质ⅲ的制备方法
WO2025137652A2 (en) 2023-12-20 2025-06-26 Grin Therapeutics, Inc. Methods of using radiprodil in the treatment of disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE254999C (enExample)
US2324123A (en) 1941-07-08 1943-07-13 Eastman Kodak Co Fog inhibitor for photographic developers
US3260723A (en) 1963-08-27 1966-07-12 Parke Davis & Co 4-phenoxy piperidines; alpha4-phenoxy piperideines
NL6501323A (enExample) 1965-02-02 1966-08-03
US3632767A (en) 1968-02-12 1972-01-04 Mallinckrodt Chemical Works Treatment of depression with 4-substituted piperidines
AU639529B2 (en) 1987-03-04 1993-07-29 Higuchi, Yoshinari Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
SK279476B6 (sk) 1989-05-17 1998-11-04 Pfizer Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
TW281670B (enExample) * 1993-09-02 1996-07-21 Hoffmann La Roche
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
WO1997023202A1 (en) 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
DE19643790A1 (de) 1996-10-30 1998-05-07 Merck Patent Gmbh Benzoxazol-Derivat
CA2251580A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amides as npy5 receptor antagonists
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
EP1024799A1 (en) 1997-10-24 2000-08-09 Warner-Lambert Company Method for treating disease-related or drug-induced dyskinesias
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
WO2000025109A1 (en) 1998-10-28 2000-05-04 Scofield Dillon F Electrodynamic particle size analyzer
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
JP2003512422A (ja) 1999-10-29 2003-04-02 メルク シャープ エンド ドーム リミテッド ベンズイミダゾールｎｍｄａ／ｎｒ２ｂアンタゴニストを使用する疼痛の治療方法

Also Published As

Publication number Publication date
CN1556805A (zh) 2004-12-22
SK287726B6 (en) 2011-07-06
JP2005515968A (ja) 2005-06-02
CZ2004233A3 (cs) 2004-12-15
KR20040041152A (ko) 2004-05-14
PT1409477E (pt) 2008-11-20
JP4322113B2 (ja) 2009-08-26
ZA200400417B (en) 2005-07-27
DE60228969D1 (enExample) 2008-10-30
NO327099B1 (no) 2009-04-20
NO20040307L (no) 2004-03-23
NZ530055A (en) 2005-07-29
PL216636B1 (pl) 2014-04-30
US7435744B2 (en) 2008-10-14
RS103903A (sr) 2007-02-05
DK1409477T3 (da) 2008-12-08
EE200400058A (et) 2004-04-15
KR100890676B1 (ko) 2009-03-26
ATE408611T1 (de) 2008-10-15
HRP20040178B1 (hr) 2013-05-31
SK1022004A3 (en) 2004-07-07
WO2003010159A1 (en) 2003-02-06
BG66441B1 (bg) 2014-08-29
EP1409477B1 (en) 2008-09-17
US20040157886A1 (en) 2004-08-12
AU2002313566B8 (en) 2003-02-18
PL367259A1 (en) 2005-02-21
EP1409477A1 (en) 2004-04-21
CA2453383A1 (en) 2003-02-06
ES2312603T3 (es) 2009-03-01
SI1409477T1 (sl) 2009-02-28
EA010162B1 (ru) 2008-06-30
BR0211393A (pt) 2004-08-17
CA2453383C (en) 2010-04-06
CN100413860C (zh) 2008-08-27
CO5560570A2 (es) 2005-09-30
EA200400213A1 (ru) 2004-08-26
UA77684C2 (en) 2007-01-15
RS50767B (sr) 2010-08-31
IL159393A0 (en) 2004-06-01
HRP20040178A2 (en) 2005-04-30
CY1109401T1 (el) 2014-07-02
HK1063464A1 (en) 2004-12-31
WO2003010159A8 (en) 2004-02-12
MXPA04000737A (es) 2004-07-08
AU2002313566B2 (en) 2007-05-24
IL159393A (en) 2011-01-31
IS7066A (is) 2003-12-05
BG108592A (bg) 2005-03-31

Similar Documents

Publication Publication Date Title
EE05429B1 (et) Karbokslhappe amiidi derivaadid, nende saamise meetod ning kasutamine
NO970501L (no) Substituerte kinazolinderivater
DE69310501D1 (de) Chinolylbenzofuran derivate als leukotrien-antagonisten
ATE195938T1 (de) 2-(1',2',4'-triazol-3'yloxymethylen)-anilide und ihre verwendung als schädlingsbekämpfungsmittel
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
EE9700282A (et) Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
EA199901102A1 (ru) Производные азетидинилпропилпиперидина, промежуточные соединения и применение в качестве антагонистов тахикинина
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
ATE148704T1 (de) Imidazo (1,2-a> pyrasin-4-on-derivate welche als ampa und nmda receptor antagonisten dienen
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
NO20013684L (no) Substituerte fenetylaminderivater
TR200000725T2 (tr) Bir monoamin oksidaz inhibitörü ve h5-HT1B antagonistinin bileşimi
PT1044186E (pt) Composto 2-benzilamino-2-fenil-acetamida substituidos
ATE270289T1 (de) Heteroaryloxypropanolamine als beta3- adrenergischer rezeptor-agonisten
CA2285535A1 (en) Benzimidazole derivative for treating allergy-related disease
ATE332695T1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2
DE59604901D1 (de) Carbamoylcarbonsäureamide
EA200400470A1 (ru) Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции
ZA956579B (en) Saccharin derivatives.
DK0531119T3 (da) N,N,N-trisubstituerede 5-bis-aminomethylen-1,3-dioxan-4,6-dioner som inhibitorer af acyl-CoA: cholesterol-acyltransferase
DK542183D0 (da) Fremgangsmade til fremstilling af acridanonderivater

Legal Events

Date Code Title Description
HC1A Change of owner name
GB1A Change in the ownership or in the address of the owner